Group 1 - The company "Renyang Yitou Niu" has shifted its financing strategy after terminating its IPO in February 2023, opting for a pledge of 100% equity in its subsidiary Hebei Kanghong Animal Husbandry for 103 million yuan to raise funds for business expansion and farm construction [1][2] - Kanghong Animal Husbandry is a core part of the company's dairy segment, established in October 2020 with a registered capital of 103 million yuan, and is recognized as one of the largest dairy farms in China with a herd size of 27,000 cows as of 2022 [1][3] - The company's IPO journey faced significant challenges, including high marketing costs and insufficient R&D investment, leading to multiple regulatory feedbacks and ultimately the withdrawal of its IPO application [2][3] Group 2 - The dairy industry is currently experiencing intense competition, with a projected 2.8% decline in raw milk production in 2024, marking the first decrease since 2018 [3] - Among 21 listed dairy companies, only 5 have achieved growth in both revenue and net profit, while 13 have seen declines in both metrics [3] - The company's previous plans for significant investments in smart farm construction and information system upgrades are now under scrutiny following the termination of its IPO, raising questions about its strategic adjustments and competitiveness in a challenging market [3]

Core Viewpoint - Chicheng Biotechnology has voluntarily withdrawn its IPO application from the Beijing Stock Exchange, which aimed to raise 210 million yuan due to various operational challenges and financial pressures [2] Group 1: Company Overview - Chicheng Biotechnology specializes in the research, production, and sales of hydrolyzed tannin products derived from natural plant materials, with applications across multiple industries including pharmaceuticals, chemicals, and textiles [2] - The company’s main products include tannic acid, gallic acid, and related biochemical compounds [2] Group 2: Financial Performance - Chicheng Biotechnology's revenue from 2021 to 2023 showed significant fluctuations, with revenues of 360 million yuan, 291 million yuan, and 312 million yuan respectively, while net profits were 61.9 million yuan, 50.3 million yuan, and 48.8 million yuan [3] - The decline in revenue and profit in 2022 was primarily due to a major client, Zhengbang Technology, facing financial difficulties, which led to a significant reduction in orders [3][4] Group 3: Cost Structure and Risks - The cost of raw materials, particularly the reliance on wubeizi and tara powder, constitutes over 60% of the company's main business costs, making it vulnerable to price fluctuations [4] - In the first half of 2024, revenue increased by 25.10%, but net profit only grew by 14.59% due to rising raw material costs [4] Group 4: Inventory and Cash Flow - The company's inventory value as a percentage of total assets was notably high, with values of 96.2 million yuan, 87.2 million yuan, and 105 million yuan, representing 19.88%, 14.77%, and 17.03% of total assets respectively [5] - High inventory levels can lead to cash flow pressures and operational inefficiencies [5] Group 5: Business Expansion - Chicheng Biotechnology established a subsidiary, Hubei Bencao Times Health Industry Co., Ltd., in 2022 to enter the cosmetics sector, but this venture is still in its early stages with limited online sales [5] - Revenue from this subsidiary was minimal, with figures of 32,200 yuan and 127,570 yuan for 2022 and 2023 respectively, indicating challenges in scaling the new business [5]

Core Viewpoint - Dongang Technology's IPO application has been terminated again after transitioning from the ChiNext to the Beijing Stock Exchange, primarily due to concerns over business innovation, performance decline risks, and the rationality of fundraising projects [1][3][4]. Group 1: IPO Process and Challenges - Dongang Technology was the first company to have its IPO application accepted in 2024, but it voluntarily withdrew its application after two rounds of inquiries from the Beijing Stock Exchange [2][3]. - This is not the first time Dongang Technology has faced challenges with its IPO; it previously withdrew its application for the ChiNext in September 2022 after receiving a second round of inquiries [2][3]. Group 2: Business Overview - Dongang Technology specializes in the research, production, and sales of professional mobile lighting tools, including various types of lamps used in specialized fields such as vehicle maintenance, construction, and emergency response [3][4]. - The company claims to have strong competitive advantages in product performance and technological innovation, primarily serving markets in Europe and North America [3][4]. Group 3: Financial Performance - From 2020 to 2024, Dongang Technology's revenue fluctuated, with figures of 178 million, 263 million, 231 million, 221 million, and 234 million yuan respectively, indicating a notable decline in 2022 and 2023 before a slight recovery in 2024 [7]. - The company's net profit also showed volatility, with a decrease in 2022 and 2023, followed by a modest increase in 2024 [7][9]. Group 4: Customer Concentration and Risks - The company has a high customer concentration, with its top three customers accounting for over 78% of total sales in recent years, raising concerns about revenue stability [9][10]. - Sales to major clients saw significant declines in 2022, attributed to external economic factors such as the Ukraine crisis and inflation [10][11]. Group 5: Fundraising and Investment Plans - Dongang Technology plans to raise 260 million yuan through its IPO, with allocations for a high-end lighting tool production base, a research and development center, and working capital [14][18]. - The company aims to enhance its production capacity and technological capabilities through these investments, despite concerns about the necessity of the projects given its recent financial performance [17][20].

Group 1 - The IPO application of Dongguan Langtaitong Technology Co., Ltd. has been terminated as of May 19, 2025, due to the withdrawal of the application by the company and its sponsor [2][6] - The company’s IPO application was accepted by the Shenzhen Stock Exchange on June 27, 2023, and it received a second round of inquiry on November 8, 2023, but has not responded to the inquiries [5][6] - The company updated its financial data on June 29, 2024, which was three months late, with the data cutoff date set at December 31, 2023 [5][6] Group 2 - Langtaitong was established in 2015 and focuses on the research, production, sales, and service of batteries, primarily for energy storage and power tools [7] - The company aimed to raise 702 million yuan through its IPO, with the funds intended for the construction of a lithium iron phosphate battery production base, a research and development center, and to supplement working capital [7] - The termination of Langtaitong's IPO is not an isolated incident, as several other companies in the new energy battery industry have also faced similar challenges in their IPO attempts since 2024 [7]

Core Viewpoint - After a four-month "suspended" review status, the company has chosen to withdraw its IPO application, leading to the termination of its listing process [2] Group 1: Company Performance - In 2024, the company reported revenue of 258 million yuan, a year-on-year decrease of 16.34%, contrasting with an average growth rate exceeding 30% over the previous three years [3] - The net profit for 2024 was 3 million yuan, a dramatic decline of 93% compared to previous years, where the lowest growth rate was 16.20% [3] Group 2: IPO Details - The company, Shenzhen Konghui Intelligent Co., Ltd., was established in 2010 and specializes in the research, production, and sales of industrial automation control products [4] - The company submitted its IPO application to the Beijing Stock Exchange on November 3, 2023, aiming to raise 163 million yuan for expansion projects and R&D [4] Group 3: Controversies and Concerns - There are significant concerns regarding the necessity and rationality of the fundraising projects, particularly the projected output ratio dropping from 18.00 to 4.75 post-expansion [4] - Despite negative cash flow from operating activities from 2020 to 2024, the company distributed cash dividends totaling 23.43 million yuan, with the controlling shareholders receiving 10 million yuan [4] - The company's reliance on major client BYD has weakened, with orders amounting to 4.774 million yuan in 2023, a decrease of over 90% year-on-year [4]

3月7日晚上，北交所公布对常州金康精工（831978）IPO终止审核的决定。常州金康精工2024年1月25日获得北交所上市委审核通过，但一直未能提交注册直到被终 止审核。公司IPＯ的保荐机构为东北证券。笔者注意到，公司列举的4家同行业可比公司2024年扣非净利润同比均是大幅下降。 文/西风 一、两实控人合计控制公司96.65%的股份表决权 公司前身有限公司成立于２００１年１０月，2014年7月整体变更为股份公司。2015年2月17日公司股票挂牌新三板。公司目前注册资本5508万元。公司控股股东、 实际控制人为钟仁康、万奕金。钟仁康、万奕金目前分别持有公司总股本的 43.64%。两人合计持有发行人 87.28%的股权，并通过一致行动协议控制常州奕仁、钟 惠丽、万丽、钟立新直接持有的发行人合计 9.37%的股份表决权，两人合计控制发行人 96.65%的股份表决权。钟仁康先生1969 年 9 月出生，现任公司董事长。万奕 金1947年12月出生，现任公司董事。 另外，一致行动人钟惠丽系发行人股东常州奕仁执行事务合伙人，与钟仁康为父女关系，万丽与董事万奕金为父女关系。 二、公司是电机绕组制造专用装备整体解决方案提供商 ...

文/梧桐兄弟 1月21日，上交所公布中国证监会对苏州高泰电子技术股份有限公司主板IPO注册程序终止的通知书，直接原因是公司及保荐机构国金证券撤回注册申请。公司IPO 在2023年8月29日获得审核通过，2023年12月1日提交注册。公司本次IPO拟募资11.55亿元。 一、上市委会议现场问询的主要问题 1.请发行人代表：（1）结合下游行业发展趋势、下游PC产品毛利率、公司技术优劣势、研发费用率、产品价格及销量情况、主要成本结构及生产方式等方面，说 明公司毛利率明显高于同行业可比公司的合理性；（2）说明未进一步与全制程外协厂商商议供货价格的原因。请保荐代表人发表明确意见。 2.请发行人代表结合行业竞争格局、下游需求变化、公司2023 年上半年经营业绩下滑、公司现有固定资产规模和产能利用率等，说明本次募投项目的必要性和合 理性，产能消化的具体措施及可行性。请保荐代表人发表明确意见。 二、2023年业绩下滑，下游应用领域主要集中于电脑 公司主营产品包括复合功能性材料、复合功能性器件及电子级追溯产品。报告期内，公司产品应用于戴尔、苹果、联想终端品牌的收入分别占同期主营业务收入 的 82.11%、84.02%、83.7 ...

近日，因广州明美新能源股份有限公司（简称"明美新能"）、保荐人撤回发行上市申请，根据 《深圳证券交易所股票发行上市审核规则（2024年修订）》第六十二条深交所决定终止其发行 上市审核。 追溯来看，2022年6月24日，明美新能创业板IPO获受理；同年7月20日，进入问询阶段；2023 年2月17日过会；2025年1月12日终止。 明美新能是一家专业从事锂离子电池模组研发、生产和销售的高新技术企业。 作为专业的锂电池PACK企业，公司一直致力于向客户提供安全、稳定、高效的锂离子电池模 组产品。公司锂离子电池模组主要应用于消费电子、工业电子设备、二轮电动车、动力和储能 领域。公司与OPPO集团、斑马技术、纬创、伟创力、大陆集团、科沃斯、环鸿电子和远景科 技集团等国内外知名品牌建立了长期稳定的合作关系。 报告期内，公司消费电子类产品销售收入占公司主营业务收入的比例分别为：62.51%、 61.72%、51.10%和40.19%，毛利率分别为：8.07%、6.97%、5.81%和8.84%。各类消费电子 产品销量及更新换代等因素将对公司相关产品的销售产生较大影响，消费电子行业周期波动将 一定程度影响公司的经营业绩。 ...

文/西风 12月8日晚上，深交所公布对浙江科峰有机硅股份有限公司创业板IPO终止审核的决定，直接原因是公司及保荐机构国金证券撤回申报。公司IPO于 2022年6月30日 获得受理，经历两轮问询后于2023年6月21日过会。公司本次IPO拟募资3.9亿元。 公司注册地浙江嘉兴，前身浙江科峰化工有限公司成立于2002年10月，2021年11月整体变更为股份公司，目前注册资本6000万元。公司控股股东为海宁科峰投资 有限公司，实际控制人为1966年出生的李云峰先生。李云峰直接及间接控制发行人 93.89%的股份，现任公司董事长兼总经理。 一、自称国内领先的嵌段硅油企业之一 公司是一家以有机硅应用材料为主业，专业从事纺织印染助剂、纳米液体分散染料及其他有机硅产品的研发、生产、销售的高新技术企业、国家级专精特新"小巨 人"企业，主要产品包括嵌段硅油、氨基硅油等后整理助剂、前处理助剂、染色印花助剂、纳米液体分散染料和六甲基二硅氧烷等。公司产品品类齐全，业务链完 整，现已成为国内领先的嵌段硅油企业之一。 公司研发的"全能型亲水氨基硅油"、"棉用嵌段聚醚亲水氨基硅油"、"染色同浴吸湿排汗剂 KF-1474"、"棉布特用亲水嵌 ...

文/梧桐兄弟 11月28日，深交所公布对杭州衡泰技术股份有限公司创业板IPO终止审核的决定，直接原因是公司及保荐机构中信证券撤回申报。公司IPO早在2023年4月14日获得 审核通过，但此后一直未提交注册。公司本次IPO拟募资6.01亿元。 一、深交所上市委会议现场问询的主要问题 深交所上市审核委员会2023年第22次审议会议于2023年4月14日召开，彼时衡泰技术IPO获得审核通过，现场问询的主要问题如下： 1、资金拆借问题。根据发行人申报材料，报告期内发行人与控股股东开曼衡泰、实际控制人、部分高管及员工发生大额资金拆借。 请发行人：（1）结合相关审批或内部决策程序，说明上述资金往来的原因及合理性；（2）说明是否存在实际控制人为发行人代垫成本费用的情形，是否存在资金 体外循环的情形；（3）结合整改规范情况，说明相关内部控制制度是否健全有效。同时，请保荐人发表明确意见。 2、信息安全问题。根据发行人申报材料，发行人是金融行业定量分析与技术供应商，主要为证券公司、银行、基金公司、保险公司等金融机构客户提供应用软件 产品和服务，产品体系覆盖各类资产的交易处理与分析、风险管理、投资分析等核心需求。 请发行人：（1） ...